{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-037042","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2021-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.388466+00:00","generated_at":"2026-06-30T04:31:48.400860+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arcus CMO Bill Grossman moves to Gilead; Kartik Krishnan takes over clinical development","bullets":["Bill Grossman, MD, PhD, resigns as CMO effective July 26, 2021, to become SVP of Oncology Clinical Research at Gilead.","Grossman will be Arcus's point of contact at Gilead for co-development activities under the alliance.","Kartik Krishnan, MD, PhD, promoted to lead Arcus clinical development, effective July 26.","Grossman will provide consulting to Arcus for up to 3 months; his stock option exercise period extended to July 1, 2022.","Krishnan joined Arcus in 2019 and has been assuming increasing responsibilities since December 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-037042","json":"https://secwatch.observer/filing/0001564590-21-037042.json","markdown":"https://secwatch.observer/filing/0001564590-21-037042.md","text":"https://secwatch.observer/filing/0001564590-21-037042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/0001564590-21-037042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/rcus-8k_20210716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:31:48.400860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a6dd59351","claim":"Bill Grossman resigned as Chief Medical Officer at Arcus Biosciences, Inc..","evidence_excerpt":"On July 16, 2021, Bill Grossman, MD, Arcus Biosciences, Inc.’s Chief Medical Officer, resigned from Arcus to become SVP of Oncology Clinical Research at Gilead Sciences, Inc., effective July 26, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/0001564590-21-037042-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}